- Oral presentation
- Open Access
Efficacy of MR-guided focused ultrasound ablation for localized adenomyosis in comparison to leiomyoma
© Coy et al; licensee BioMed Central Ltd. 2015
Published: 30 June 2015
Symptomatic localized adenomyosis is generally treated conservatively, or with more radical treatments such as hysterectomy. An effective non-invasive therapy is needed, especially for those who wish to preserve their fertility. MR-guided Focused Ultrasound ablation (MRgFUS) has been shown as an effective treatment for symptomatic uterine leiomyomas with a large non-perfused volume (NPV) immediately after treatment. Our specific aim was to compare the change in NPV in subjects with localized adenomyomas treated with MRgFUS, with the change in NPV in subjects treated with MRgFUS for symptomatic uterine leiomyomas to determine if similar results were achieved in the localized adenomyoma cohort.
With IRB approval, we performed a HIPAA compliant retrospective review of women treated with MRgFUS at our comprehensive treatment center for symptomatic localized adenomyosis. We matched cases with leiomyoma bearing-controls with the following criteria: 1) Similar baseline total lesion volume. 2) Similar number of lesions at baseline. 3) Similar age. Subjects who had imaging performed both prior and immediately post-treatment were included. All lesions were contoured on the T1 post-contrast sagittal series, and volumes were calculated with a validated proprietary software. All contours were confirmed by two genitourinatry trained radiologists. The software automatically calculated the total lesion volume and its perfused volume, from which we derived the NPV by subtracting the perfused lesion volume from the total lesion volume.
Results and conclusions
10 lesions in 9 subjects were analyzed. Adenomyoma and leiomyoma cohorts were similar in baseline characteristics including age (42 vs. 43) and mean baseline total lesion volume (96cc vs. 97cc), respectively. Post-tx characteristics were also similar between adenomyoma and leiomyoma cohorts in mean total lesion volume (97cc vs. 90 cc), mean post-tx NPV (41cc vs. 52cc) and sonication number (74 vs. 65), respectively.
From our results we can conclude that MRgFUS can offer significant reduction in perfused volume of localized adenomyosis similar to leiomyoma, and may offer complete ablation of the adenomyoma. Therefore indicating MRgFUS may be a viable non-invasive treatment for patients with symptomatic adenomyosis, and may offer an alternative to conventional therapies.
Center for Computer Vision and Imaging Biomarkers, Department of Radiology, David Geffen School of Medicine, University of California, Los Angeles
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.